Status:
RECRUITING
CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease
Lead Sponsor:
ShenZhen Cell Valley
Collaborating Sponsors:
First Affiliated Hospital of China Medical University
Conditions:
Relapsed/Refractory Autoimmune Diseases
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
In this study, CD19 CAR-T cells were administered to patients with relapsed/refractory autoimmune diseases. This study intends to use retroviral vector-based tandem CAR-T cells targeting CD19 to treat...
Detailed Description
This is a prospective, single-center, open, single-arm, dose-escalation clinical trial to evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed/refractory autoimmune disease...
Eligibility Criteria
Inclusion
- age 18-65 years (including threshold) and gender;
- positive expression of CD19 in peripheral blood B cells as determined by flow cytometry;
- the function of vital organs meets the following requirements:
- Bone marrow function needs to meet the following requirements: a. White blood cell count ≥3×109/L; b. Neutrophil count ≥1×109/L (no colony-stimulating factor treatment within 2 weeks prior to the examination); c. Hemoglobin ≥60g/L;
- Liver function: ALT≤3×ULN (except for elevated ALT caused by inflammatory myopathy); AST≤3×ULN (except for AST elevation caused by inflammatory myopathy); TBIL≤1.5×ULN (except for Gilbert's disease).
- TBIL≤1.5×ULN (except Gilbert's syndrome, total bilirubin≤3.0×ULN);
- Renal function: creatinine clearance (CrCl) ≥ 30 ml/minute (Cockcroft/Gault formula, except for disease-induced decline in CrCl);
- Coagulation: international normalized ratio (INR) ≤ 1.5 x ULN, prothrombin time (PT) ≤ 1.5 x ULN.
- Cardiac function: hemodynamic stability;
- female subjects of childbearing potential and male subjects with a partner of childbearing potential are required to use medically approved contraception or be abstinent from sexual intercourse for at least 6 months during and after study treatment; female subjects of childbearing potential must have had a negative serum HCG test within 7 days prior to study enrollment and must not be breastfeeding;
- Voluntarily participate in this clinical study and sign the informed consent form, good compliance and cooperate with follow-up visits.
- Specific inclusion criteria:
- Relapsed refractory systemic lupus erythematosus.
- meets the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE;
- have a Disease Activity Score SLEDAI⁃2000 ≥ 6; and have at least one British Isles Lupus Assessment Group Index (BILAG-2004) Category A (severe manifestations) or two Category B (moderate manifestations) organ scores, or both; or have a Disease Activity Score SLEDAI-2000 ≥ 8;
- Definition of relapse-refractory: failure of conventional treatment for more than 6 months or recurrence of disease activity after remission.
- Relapsing Refractory/Progressive Diffuse Systemic Sclerosis
- meets the 2013 ACR's classification criteria for systemic sclerosis consistent with a diffuse presentation
- is positive for antibodies related to systemic sclerosis;
- diffuse cutaneous sclerosis manifestations or active interstitial lung disease (HRCT suggestive of ground-glass exudates);
- definition of relapsing-refractory: failure of conventional treatment for more than 6 months or recurrence of disease activity after remission.
- Definition of Progressive: Rapid cutaneous progression (\>25% increase in mRSS); or pulmonary progression (10% decrease in FVC, or \>5% decrease in FVC with 15% decrease in DLCO).
- Note: It is sufficient if one of Articles 4 and 5 is fulfilled.
- Relapsed refractory/progressive inflammatory myopathy
- meets the 2017 EULAR/ACR classification criteria for inflammatory myopathies (including DM , PM, ASS, and NM);
- is positive for antibodies to myositis;
- in those with muscle involvement, an MMT-8 score of less than 142 and abnormal findings on at least two of the following five core measurements (PhGA, PtGA, or Extramuscular Disease Activity Score ≥2; Total HAQ Score ≥0.25); Myosin level 1.5 times the upper limit of the normal range); or MMT-8 ≥142 in the presence of active interstitial lung disease (HRCT suggestive of ground-glass exudates);
- Definition of relapse refractory: failure of conventional treatment for more than 6 months or recurrence of disease activity after remission.
- Definition of progressive: the presence of exacerbation of myositis or rapidly progressive interstitial pneumonia.
- Note: It is sufficient if one of Articles 4 and 5 is fulfilled.
- Relapsed Refractory/Progressive Immune Thrombocytopenia
- meets the 2019 American Society of Hematology (ASH) classification criteria for immune thrombocytopenia;
- have bone marrow morphology characterized by increased or normal megakaryocytes with impaired maturation;
- exclude other secondary thrombocytopenia
- Definition of recurrent refractory: a patient who fails to achieve a satisfactory outcome after first-line standard therapy (e.g., glucocorticoids), including a full dose and course of therapy, i.e., platelet counts that cannot be maintained at a safe level (generally considered to be platelet counts \> 30 × 10⁹ /L and without overt bleeding symptoms).
- Definition of progressive: a sustained decline in platelet count over the course of the disease, or a progressive worsening of bleeding symptoms, which may be accompanied by signs such as splenomegaly, and a progressively worse response to conventional therapy.
- Note: It is sufficient if one of Articles 4 and 5 is fulfilled.
Exclusion
- A history of severe drug allergies or sensitivities;
- the presence or suspicion of fungal, bacterial, viral or other infections that are uncontrolled or require treatment
- persons with central nervous system disorders caused by ADs or not caused by ADs.
- those with intolerable cardiac function;
- subjects with congenital immunoglobulin defects.
- history of malignant tumors within the last five years.
- end-stage renal failure;
- subjects with positive Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb) and peripheral blood HBV DNA titer higher than the upper limit of the test; subjects with positive antibody to Hepatitis C virus (HCV) and peripheral blood HCV RNA; subjects with positive antibody to Human Immunodeficiency Virus (HIV); and subjects with a positive test for Syphilis;
- mental illness and severe cognitive impairment;
- have participated in other clinical trials within 3 months prior to enrollment;
- immunosuppressants or biologics with a therapeutic effect for the indication within five half-lives prior to enrollment
- women who are pregnant or intend to become pregnant;
- subjects who, in the opinion of the investigator, have other reasons for not being included in the study.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT07193667
Start Date
October 1 2025
End Date
December 1 2027
Last Update
September 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
No. 155, The First Affiliated Hospital of China Medical University, Nanjing North Street, Heping District, Shenyang, Liaoning Province
Shenyang, Liaoning, China, 110001